By Billy Candra 
A landmark study by researchers at the University of Cambridge has provided compelling evidence that this preventative surgical procedure, known as bilateral salpingo-oophorectomy (BSO), is associated with a substantial reduction in the risk of early death among women with BRCA1 and BRCA2 pathogenic variants (PVs) who have previously been diagnosed with breast cancer. Crucially, the extensive research, published in The Lancet Oncology, also found no evidence of serious adverse long-term side effects such as heart disease, stroke, or depression, which had been a lingering concern in the medical community.
The Study’s Breakthrough Findings on Survival and Secondary Cancers
The Cambridge study, a collaborative effort with the National Disease Registration Service (NDRS) in NHS England, analyzed electronic health records and genetic testing data from 3,400 women in the UK carrying either a BRCA1 or BRCA2 pathogenic variant. Approximately 1,700 women were identified for each variant, with 850 BRCA1 carriers and 1,000 BRCA2 carriers having undergone BSO surgery.
The results revealed a significant positive impact on overall survival. Women who underwent BSO were approximately half as likely to die from cancer or any other cause during the median 5.5-year follow-up period. This life-saving benefit was particularly pronounced in BRCA2 carriers, who experienced a 56% reduction in early death risk, compared to a still substantial 38% reduction for BRCA1 carriers. Beyond the immediate survival benefits, the study also demonstrated that these women faced a roughly 40% lower risk of developing a second primary cancer, further solidifying the preventative power of BSO.
While the research team acknowledges that proving absolute causation in observational studies is challenging, the overwhelming strength and consistency of the evidence strongly point towards BSO as a direct cause of these improved outcomes. This finding is poised to significantly impact clinical guidelines and patient counseling for a highly vulnerable population.
Understanding BRCA Genes and Associated Risks
To fully appreciate the significance of these findings, it is essential to understand the role of BRCA1 and BRCA2 genes. These genes are tumor suppressors, meaning they produce proteins that help repair damaged DNA and, in turn, help ensure the stability of the cell’s genetic material. When either of these genes carries a pathogenic variant (a mutation), it loses its ability to function correctly. This genetic defect can lead to an accumulation of DNA damage, increasing the risk of uncontrolled cell growth and cancer development.
Women with BRCA1 or BRCA2 pathogenic variants face a significantly elevated lifetime risk of developing breast and ovarian cancer. For instance, women with a BRCA1 mutation have an estimated lifetime risk of breast cancer ranging from 45% to 85% and an ovarian cancer risk between 39% and 63%. For BRCA2 carriers, the lifetime breast cancer risk is similarly high, ranging from 40% to 85%, with an ovarian cancer risk between 11% and 27%. These figures are starkly higher than the general population’s risks (approximately 13% for breast cancer and less than 1.5% for ovarian cancer).
The ovarian cancers associated with BRCA mutations, particularly high-grade serous ovarian cancer, are often aggressive and difficult to detect in their early stages, leading to poor prognoses. This grim reality has historically underscored the urgent need for effective preventative strategies for high-risk individuals.
The Evolution of Risk-Reducing Salpingo-Oophorectomy (RRSO)
The discovery of the BRCA1 gene in 1994 and BRCA2 in 1995 revolutionized cancer genetics, paving the way for targeted genetic testing and personalized risk management. Following these discoveries, medical professionals began to recommend risk-reducing salpingo-oophorectomy (RRSO), which involves the surgical removal of both ovaries and fallopian tubes, for women with BRCA pathogenic variants. This recommendation was based on initial studies demonstrating an approximately 80% reduction in the risk of developing ovarian cancer.
The timing of this surgery is crucial and varies by gene variant: typically recommended between ages 35 and 40 for BRCA1 carriers, and between ages 40 and 45 for BRCA2 carriers. These age ranges are chosen to balance the desire to complete childbearing with the increasing risk of ovarian cancer onset.
However, despite its proven efficacy in preventing ovarian cancer, BSO has always been accompanied by concerns about its potential unintended consequences. The removal of the ovaries, which are the body’s primary source of estrogen, induces immediate surgical menopause. This can lead to a range of challenging symptoms, including hot flashes, night sweats, sleep disturbances, mood changes, and long-term risks such as bone density loss and cardiovascular issues. For women with a prior history of breast cancer, managing these symptoms is particularly complex, as hormone replacement therapy (HRT), a common treatment for menopausal symptoms, is often contraindicated due to concerns about stimulating breast cancer recurrence. The overall impact of BSO on the long-term health and survival of BRCA1 and BRCA2 carriers, especially those with a history of breast cancer, had remained a significant area of uncertainty.
Methodology: A Novel Approach to an Ethical Dilemma
Traditionally, the "gold standard" for evaluating the efficacy and safety of medical interventions is a randomized controlled trial (RCT). In an RCT, participants are randomly assigned to either receive the intervention (BSO, in this case) or a control (no BSO), allowing researchers to rigorously compare outcomes. However, conducting an RCT for BSO in women with BRCA pathogenic variants would be ethically indefensible. Randomly assigning some high-risk women to not receive a procedure known to dramatically reduce their ovarian cancer risk would expose them to substantially greater, avoidable harm, including a higher likelihood of developing and potentially dying from ovarian cancer.
To circumvent this ethical obstacle, the Cambridge research team employed an innovative approach, leveraging the vast and meticulously curated electronic health records and genetic testing data from NHS England’s National Disease Registration Service (NDRS). This allowed them to conduct a large-scale, observational study, meticulously comparing the long-term outcomes of BRCA1 and BRCA2 carriers with a history of breast cancer who either underwent BSO or did not. The scale of the dataset — 3,400 women — provided a robust foundation for drawing statistically significant conclusions, making it the first study of its kind to provide such comprehensive insights into overall survival and secondary effects.
Professor Antonis Antoniou, from the Department of Public Health and Primary Care and the study’s senior author, emphasized the methodological innovation: "Our findings will be crucial for counselling women with cancer linked to one of the BRCA1 and BRCA2 variants, allowing them to make informed decisions about whether or not to opt for this operation. The study also highlights the power of exceptional NHS datasets in driving impactful, clinically relevant research."
Addressing Concerns: No Link to Heart Disease, Stroke, or Depression
One of the most significant findings of the Cambridge study was the absence of an increased risk of other long-term health issues previously associated with early menopause or BSO in the general population. Concerns about conditions like heart disease, stroke, and depression had often factored into the difficult decision-making process for women considering BSO. Previous studies on the general population undergoing oophorectomy, often for benign gynecological conditions, had suggested potential links to increased cardiovascular risk and mental health issues.
However, the Cambridge researchers found no such link among the BRCA1 and BRCA2 carriers in their cohort. This reassuring discovery suggests that for this specific high-risk population, the profound benefits of cancer prevention and improved survival far outweigh, and potentially negate, any generalized risks previously observed in different contexts.
Hend Hassan, the first author of the study and a PhD student at the Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, and Wolfson College, Cambridge, articulated this reassurance: "We know that removing the ovaries and fallopian tubes dramatically reduces the risk of ovarian cancer, but there’s been a question mark over the potential unintended consequences that might arise from the sudden onset of menopause that this causes. Reassuringly, our research has shown that for women with a personal history of breast cancer, this procedure brings clear benefits in terms of survival and a lower risk of other cancers without the adverse side effects such as heart conditions or depression."
Expert Perspectives and Clinical Impact
The definitive nature of these findings is expected to have a profound and immediate impact on clinical practice. Genetic counselors and oncologists will now have robust data to present to their patients, offering a clearer picture of the comprehensive benefits of BSO beyond just ovarian cancer prevention. This clarity is particularly vital for women already grappling with a breast cancer diagnosis, for whom the prospect of further surgery and early menopause can be daunting.
Patient advocacy groups, such as Breast Cancer Now and Ovarian Cancer Action, are likely to welcome these findings, as they provide powerful ammunition for informed decision-making and support for women at high genetic risk. The study reinforces the importance of genetic testing for all women diagnosed with breast cancer, especially those under 50 or with a family history, to identify those who could benefit from this life-extending intervention.
Bridging the Health Equity Gap
Despite the clear and now further substantiated benefits of BSO, the study also uncovered concerning disparities in its uptake. The data revealed that most women undergoing BSO in the study cohort were white. Black and Asian women were approximately half as likely to undergo the procedure compared to their white counterparts. Furthermore, women residing in less deprived areas showed a higher likelihood of having BSO compared to those in the most-deprived categories.
These disparities highlight critical health equity issues within the healthcare system. Potential reasons for these discrepancies could include differences in access to genetic counseling, cultural perceptions of preventative surgery, language barriers, socioeconomic factors influencing ability to take time off for surgery and recovery, or biases in healthcare provision.
Hassan emphasized the urgency of addressing these inequities: "Given the clear benefits that this procedure provides for at-risk women, it’s concerning that some groups of women are less likely to undergo it. We need to understand why this is and encourage uptake among these women." This calls for targeted public health campaigns, improved access to genetic services in underserved communities, and culturally sensitive patient education to ensure that all eligible women, regardless of their background, can access this life-saving procedure.
The Power of Real-World Data and Future Directions
This study stands as a powerful testament to the utility of large-scale, real-world health datasets, such as those maintained by the NHS. In an era where traditional RCTs are not always feasible or ethical, leveraging existing, high-quality electronic health records provides an invaluable resource for generating clinically relevant evidence and improving patient care. The NDRS’s meticulous collection and curation of data were instrumental in enabling this groundbreaking research.
The findings open several avenues for future research. While the study established the overall survival benefit, further investigation into the precise mechanisms by which BSO reduces the risk of second cancers and non-cancer deaths could yield deeper biological insights. Research into tailored approaches for managing surgical menopause symptoms, particularly for breast cancer survivors who cannot use HRT, remains crucial. Additionally, studies focusing on the psychosocial impact of BSO across diverse populations could further refine patient support strategies.
Ultimately, this research contributes significantly to the evolving landscape of personalized cancer medicine. By providing robust evidence for a preventative strategy, it empowers women with BRCA pathogenic variants and their clinicians to make more informed, confident decisions that can dramatically improve long-term health outcomes and extend lives.
Funding and Collaborative Efforts
The research was generously funded by Cancer Research UK, a leading charity dedicated to saving lives through research, with additional support from the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre. This collaborative funding highlights the national priority placed on improving outcomes for cancer patients.
Towards a New Era of Cancer Care: The Cambridge Cancer Research Hospital
This pivotal study also underscores the broader vision for cancer care and research in Cambridge. The University of Cambridge and Addenbrooke’s Charitable Trust (ACT) are actively fundraising for a new, state-of-the-art Cambridge Cancer Research Hospital. This ambitious project, a partnership with Cambridge University Hospitals NHS Foundation Trust, is designed to transform how cancer is diagnosed and treated. It aims to serve patients across the East of England while fostering world-leading research that promises to change the lives of cancer patients not just in the UK, but globally. The success of studies like this one demonstrates the profound impact that dedicated research infrastructure and collaborative efforts can have on public health.
